Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management, and Polyomavirus and related diseases.
Résultats du suivi à 10 ans de l’association nivolumab plus ipilimumab dans le mélanome avancé issus de l’essai de phase 3, CheckMate 067
Chemotherapy-induced weight gain in early-stage breast cancer: a prospective matched cohort study reveals associations with inflammation and gut dysbiosis.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement
Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement
Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors.
Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program.
Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma
ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy.